Cardiovascular Risk Factors and LCH in Adults

NCT00483925 | Unknown

• 1 other identifier: ES 511
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation and hypopituitarism, conditions associated with increased risk of cardiovascular diseases. Objective: To investigate glucose and lipid metabolism, insulin resistance, structural arterial and functional endothelial properties in patients with multisystem LCH in a prospective, observational study. Interventions:Cardiovascular risk factors: arterial blood pressure, lipid profile, mathematical indices of insulin resistance (IR), intima media thickness, brachial artery flow mediated dilatation, dynamic indices of IR, pituitary function and C-reactive protein will be estimated in patients with LCH and in a control group matched for gender, age, BMI and smoking habits.

Conditions

Histiocytosis, Langerhans-Cell

Keywords

Langerhans cell histiocytosis; flow mediated dilatation; intima media thickness; insulin resistance; hypopituitarism; glucose and lipid metabolism,; structural arterial and functional endothelial properties in patients with multisystem LCH

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• diagnostic criteria for "definitive diagnosis" of LCH

You may not qualify if:

• not participate in strenuous physical activities, on a balanced isocaloric diet for at least 4 weeks prior to the study

Sponsors & Collaborators

• Laikο General Hospital, Athens: lead

Study Sites (1)

Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital,

Athens, 11527, Greece

RECRUITING

Related Publications (3)

• Alexandraki K, Protogerou AD, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J, Panidis D, Diamanti-Kandarakis E. Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones (Athens). 2006 Apr-Jun;5(2):126-36. doi: 10.14310/horm.2002.11176.

  PMID: 16807225 BACKGROUND

• Makras P, Samara C, Antoniou M, Zetos A, Papadogias D, Nikolakopoulou Z, Andreakos E, Toloumis G, Kontogeorgos G, Piaditis G, Kaltsas GA. Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH). Neuroradiology. 2006 Jan;48(1):37-44. doi: 10.1007/s00234-005-0011-x. Epub 2005 Nov 15.

  PMID: 16292545 BACKGROUND

• Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E, Danesino C. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003 Nov;39(16):2341-8. doi: 10.1016/s0959-8049(03)00672-5.

  PMID: 14556926 RESULT

MeSH Terms

Conditions

Histiocytosis, Langerhans-Cell; Insulin Resistance; Hypopituitarism

Condition Hierarchy (Ancestors)

Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases

Study Officials

• Gregory Kaltsas, MD, FRCP

  Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital

  STUDY DIRECTOR

Central Study Contacts

Gregory Kaltsas, MD, FRCP

CONTACT

00302107462657; gkaltsas@endo.gr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: June 6, 2007
• First Posted: June 8, 2007
• Study Start: September 1, 2005
• Last Updated: June 8, 2007

Record last verified: 2007-06

Locations

GR (1)